Vertex: 52% of patients in telaprevir trial maintain undetectable hep. C RNA

[Guest guest]

http://www.forbes.com/afxnewslimited/feeds/afx/2008/06/09/afx5094603.html

Thomson Financial News

Vertex: 52% of patients in telaprevir trial maintain undetectable hep. C RNA

06.09.08, 9:05 AM ET

NEW YORK (Thomson Financial) - Vertex Pharmaceuticals Inc. Monday said an

interim analysis of an ongoing Phase 2b study evaluating telaprevir-based

treatment in patients with genotype 1 chronic hepatitis C virus (HCV) infection

showed 52% of the patients maintained undetectable HCV RNA 12 weeks after

treatment.

All patients in the trial had previously been unable to achieve sustained

virologic response with at least one prior pegylated interferon and ribavirin

regimen.

The company is developing telaprevir for the treatment of HCV in collaboration

with Tibotec. Based on these data, Vertex and Tibotec are planning to initiate a

Phase 3 clinical trial in patients who have failed treatment with prior

pegylated interferon and ribavirin.

_________________________________________________________________

It’s easy to add contacts from Facebook and other social sites through Windows

Live™ Messenger. Learn how.

https://www.invite2messenger.net/im/?source=TXT_EML_WLH_LearnHow

[Guest guest]

http://www.forbes.com/afxnewslimited/feeds/afx/2008/06/09/afx5094603.html

Thomson Financial News

Vertex: 52% of patients in telaprevir trial maintain undetectable hep. C RNA

06.09.08, 9:05 AM ET

NEW YORK (Thomson Financial) - Vertex Pharmaceuticals Inc. Monday said an

interim analysis of an ongoing Phase 2b study evaluating telaprevir-based

treatment in patients with genotype 1 chronic hepatitis C virus (HCV) infection

showed 52% of the patients maintained undetectable HCV RNA 12 weeks after

treatment.

All patients in the trial had previously been unable to achieve sustained

virologic response with at least one prior pegylated interferon and ribavirin

regimen.

The company is developing telaprevir for the treatment of HCV in collaboration

with Tibotec. Based on these data, Vertex and Tibotec are planning to initiate a

Phase 3 clinical trial in patients who have failed treatment with prior

pegylated interferon and ribavirin.

_________________________________________________________________

It’s easy to add contacts from Facebook and other social sites through Windows

Live™ Messenger. Learn how.

https://www.invite2messenger.net/im/?source=TXT_EML_WLH_LearnHow